These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 23996484)

  • 1. Farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax in acute myelogenous leukemia cells.
    Ding H; McDonald JS; Yun S; Schneider PA; Peterson KL; Flatten KS; Loegering DA; Oberg AL; Riska SM; Huang S; Sinicrope FA; Adjei AA; Karp JE; Meng XW; Kaufmann SH
    Haematologica; 2014 Jan; 99(1):60-9. PubMed ID: 23996484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ras homologue enriched in brain is a critical target of farnesyltransferase inhibitors in non-small cell lung cancer cells.
    Zheng H; Liu A; Liu B; Li M; Yu H; Luo X
    Cancer Lett; 2010 Nov; 297(1):117-25. PubMed ID: 20554106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity.
    Basso AD; Mirza A; Liu G; Long BJ; Bishop WR; Kirschmeier P
    J Biol Chem; 2005 Sep; 280(35):31101-8. PubMed ID: 16006564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Driven to death: Inhibition of farnesylation increases Ras activity and promotes growth arrest and cell death [corrected].
    Geryk-Hall M; Yang Y; Hughes DP
    Mol Cancer Ther; 2010 May; 9(5):1111-9. PubMed ID: 20406948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tipifarnib-induced apoptosis in acute myeloid leukemia and multiple myeloma cells depends on Ca2+ influx through plasma membrane Ca2+ channels.
    Yanamandra N; Buzzeo RW; Gabriel M; Hazlehurst LA; Mari Y; Beaupre DM; Cuevas J
    J Pharmacol Exp Ther; 2011 Jun; 337(3):636-43. PubMed ID: 21378206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumorigenic activity and therapeutic inhibition of Rheb GTPase.
    Mavrakis KJ; Zhu H; Silva RL; Mills JR; Teruya-Feldstein J; Lowe SW; Tam W; Pelletier J; Wendel HG
    Genes Dev; 2008 Aug; 22(16):2178-88. PubMed ID: 18708578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide.
    Karp JE; Flatten K; Feldman EJ; Greer JM; Loegering DA; Ricklis RM; Morris LE; Ritchie E; Smith BD; Ironside V; Talbott T; Roboz G; Le SB; Meng XW; Schneider PA; Dai NT; Adjei AA; Gore SD; Levis MJ; Wright JJ; Garrett-Mayer E; Kaufmann SH
    Blood; 2009 May; 113(20):4841-52. PubMed ID: 19109557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytotoxicity of farnesyltransferase inhibitors in lymphoid cells mediated by MAPK pathway inhibition and Bim up-regulation.
    Ding H; Hackbarth J; Schneider PA; Peterson KL; Meng XW; Dai H; Witzig TE; Kaufmann SH
    Blood; 2011 Nov; 118(18):4872-81. PubMed ID: 21673341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells.
    Niessner H; Beck D; Sinnberg T; Lasithiotakis K; Maczey E; Gogel J; Venturelli S; Berger A; Mauthe M; Toulany M; Flaherty K; Schaller M; Schadendorf D; Proikas-Cezanne T; Schittek B; Garbe C; Kulms D; Meier F
    J Invest Dermatol; 2011 Feb; 131(2):468-79. PubMed ID: 20944654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Farnesyltransferase inhibitors reverse altered growth and distribution of actin filaments in Tsc-deficient cells via inhibition of both rapamycin-sensitive and -insensitive pathways.
    Gau CL; Kato-Stankiewicz J; Jiang C; Miyamoto S; Guo L; Tamanoi F
    Mol Cancer Ther; 2005 Jun; 4(6):918-26. PubMed ID: 15956249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
    Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
    Cancer Res; 2013 Feb; 73(4):1340-51. PubMed ID: 23243017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The farnesyl transferase inhibitor, tipifarnib, is a potent inhibitor of the MDR1 gene product, P-glycoprotein, and demonstrates significant cytotoxic synergism against human leukemia cell lines.
    Medeiros BC; Landau HJ; Morrow M; Lockerbie RO; Pitts T; Eckhardt SG
    Leukemia; 2007 Apr; 21(4):739-46. PubMed ID: 17268526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cloning and characterization of a human BCR/ABL-positive cell line, K562/RR, resistant to the farnesyltransferase inhibition by tipifarnib.
    Miyoshi T; Nagai T; Kikuchi S; Ohmine K; Nakamura M; Hanafusa T; Komatsu N; Ozawa K
    Exp Hematol; 2007 Sep; 35(9):1358-65. PubMed ID: 17656006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib: identification of T-cell ALL and FAB M5 AML as the most sensitive subsets.
    Goemans BF; Zwaan CM; Harlow A; Loonen AH; Gibson BE; Hählen K; Reinhardt D; Creutzig U; Heinrich MC; Kaspers GJ
    Blood; 2005 Nov; 106(10):3532-7. PubMed ID: 16051737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor effects of low-dose tipifarnib on the mTOR signaling pathway and reactive oxygen species production in HIF-1α-expressing gastric cancer cells.
    Egawa N; Tanaka T; Matsufuji S; Yamada K; Ito K; Kitagawa H; Okuyama K; Kitajima Y; Noshiro H
    FEBS Open Bio; 2021 May; 11(5):1465-1475. PubMed ID: 33773069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of apoptosis induction by concomitant inhibition of MEK, mTOR, and Bcl-2 in human acute myelogenous leukemia cells.
    Zhang W; Ruvolo VR; Gao C; Zhou L; Bornmann W; Tsao T; Schober WD; Smith P; Guichard S; Konopleva M; Andreeff M
    Mol Cancer Ther; 2014 Jul; 13(7):1848-59. PubMed ID: 24739393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Follicle-stimulating hormone activation of hypoxia-inducible factor-1 by the phosphatidylinositol 3-kinase/AKT/Ras homolog enriched in brain (Rheb)/mammalian target of rapamycin (mTOR) pathway is necessary for induction of select protein markers of follicular differentiation.
    Alam H; Maizels ET; Park Y; Ghaey S; Feiger ZJ; Chandel NS; Hunzicker-Dunn M
    J Biol Chem; 2004 May; 279(19):19431-40. PubMed ID: 14982927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Farnesyltransferase inhibition in hematologic malignancies: the clinical experience with tipifarnib.
    Martinelli G; Iacobucci I; Paolini S; Ottaviani E
    Clin Adv Hematol Oncol; 2008 Apr; 6(4):303-10. PubMed ID: 18496498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Silencing of RHEB inhibits cell proliferation and promotes apoptosis in colorectal cancer cells via inhibition of the mTOR signaling pathway.
    Tian Y; Shen L; Li F; Yang J; Wan X; Ouyang M
    J Cell Physiol; 2020 Jan; 235(1):442-453. PubMed ID: 31332784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia.
    Raponi M; Lancet JE; Fan H; Dossey L; Lee G; Gojo I; Feldman EJ; Gotlib J; Morris LE; Greenberg PL; Wright JJ; Harousseau JL; Löwenberg B; Stone RM; De Porre P; Wang Y; Karp JE
    Blood; 2008 Mar; 111(5):2589-96. PubMed ID: 18160667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.